In accordance with this finding expression of IL-6R on T cells from IFN-β-treated MS patients was significantly diminished compared to therapy-naive MS patients (Figure 4B), suggesting that IFN-β therapy targets IL-6 signaling and thereby renders T cells sensitive to Treg control (Figure 4C). Here, IL6 is linked to myeloid sarcoma.